| 微生物来源的ACAT抑制剂的研究进展 |
| |
| 引用本文： | 陆颖菲,高向东,顾觉奋. 微生物来源的ACAT抑制剂的研究进展[J]. 中国新药杂志, 2011, 0(15) |
| |
| 作者姓名： | 陆颖菲 高向东 顾觉奋 |
| |
| 作者单位： | 中国药科大学生命科学与技术学院; |
| |
| 摘 要： | 酰基辅酶A-胆固醇酰基转移酶(ACAT)抑制剂是近年来降血脂和抗动脉粥样硬化药物研究的热点。两种全合成的药物在Ⅲ期临床试验被证明对动脉粥样硬化无效甚至有害,而天然抑制剂在结构上与合成抑制剂有很大的不同。筛选与研究天然抑制剂,作为药物设计的先导物,有可能开发出一些疗效显著的药物。本文综述了微生物来源的ACAT抑制剂的研究进展。
|
| 关 键 词： | ACAT抑制剂 动脉粥样硬化 降血脂 微生物来源 |
Current status of studies on ACAT inhibitors from microorganisms |
| |
| LU Ying-fei,GAO Xiang-dong,GU Jue-fen. Current status of studies on ACAT inhibitors from microorganisms[J]. Chinese Journal of New Drugs, 2011, 0(15) |
| |
| Authors: | LU Ying-fei GAO Xiang-dong GU Jue-fen |
| |
| Affiliation: | LU Ying-fei,GAO Xiang-dong,GU Jue-fen(Institute of Life Science and Technology,China Pharmaceutical University,Nanjing 210009,China) |
| |
| Abstract: | ACAT was viewed as potential therapeutic targets since the cholesterol-lowering and anti-atherosclerosis activity of its inhibitors.The synthetic drugs pactimibe and avasimibe proved inefficient in clinical trials.Nevertheless,natural inhibitors were structurally different.As lead compounds,they were expected to provide leads for drug design and development.The current status of studies on ACAT inhibitors from microorganisms was reviewed. |
| |
| Keywords: | ACAT inhibitors atherosclerosis lipid-lowering from microorganisms |
| 本文献已被 CNKI 等数据库收录！ |
|
